In spite of plummeting valuation, 23andMe still aims to pivot into biotech

23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.

Om Podcasten

Monday through Friday, Marketplace demystifies the digital economy in less than 10 minutes. We look past the hype and ask tough questions about an industry that’s constantly changing.